1,3-Beta-glucan synthase

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

Retrieved on: 
Thursday, July 29, 2021
Antifungals, Infectious diseases, Branches of biology, Pathogenic microbes, Yeasts, Medical specialties, Echinocandins, Candida auris, Cándida, 1,3-Beta-glucan synthase, Caspofungin

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • The New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

Retrieved on: 
Monday, July 12, 2021
Antifungals, Branches of biology, Medical specialties, Infectious diseases, Yeasts, Pathogenic microbes, Echinocandins, Candida auris, Multiple drug resistance, Azole, Cándida, 1,3-Beta-glucan synthase

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains.

1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 20, 2020
Health, Pharmaceutical, Polysaccharides, 1,3-Beta-glucan synthase, Chemical substances, Chemistry, Glucan, Beta-glucan, Physical sciences, PGG-glucan

The "1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the 1,3-Beta-Glucan Synthase Inhibitor pipeline landscape is provided, which includes the topic overview and 1,3-Beta-Glucan Synthase Inhibitor mechanism of action.
  • The assessment part of the report embraces, in-depth 1,3-Beta-Glucan Synthase Inhibitor commercial assessment and clinical assessment of the pipeline products under development.
  • Elucidated 1,3-Beta-Glucan Synthase Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.